FLT3 and acute myeloid leukemia: While ERK is engaged simultaneously, ensuring complementary regulation of survival and proliferation pathways in FLT3-ITD AML, driven by RAS/MEK signaling downstream of FLT3-ITD, it promotes leukemic proliferation and metabolic remodeling and contributes to adaptive resistance following FLT3 inhibitor therapy [122].